Sequenom, Inc.

ACTIVE

531 S Spring St FL 2, Burlington, North Carolina, United Stateswomenshealth.labcorp.comSubsidiary501–1,000 employeesEstablished: 1994-01-01

Part of laboratory corp. of america holdings

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1994

Overview

Trial Phase Distribution

No trial phase data available

Trial Status Distribution

Completed

73.1%

Enrolling By Invitation

3.9%

Recruiting

15.4%

Terminated

7.7%

Clinical Trials

Trials sponsored by this organization (26)

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

Recruiting

observational

Apr 2026500 participants

The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

Completed

observational

Jun 20191,500 participants

Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test

Completed

observational

Oct 2018444 participants

Compliant Analysis of Patient Samples and Data

Enrolling By Invitation

observational

Mar 20182,000 participants

Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

Recruiting

observational

Oct 20153,000 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations

Sequenom, Inc.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (26)

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

Non-Invasive Preeclampsia Screening and Biobank

Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit

Clinical Follow-up of Pregnant Subjects Undergoing NIPT

The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test

Compliant Analysis of Patient Samples and Data

Specimen Collection from Patients with Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay

Approvals

News